Credit Suisse’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.94M | Sell |
405,846
-46,931
| -10% | -$218K | ﹤0.01% | 1871 |
|
|
2023
Q4 | $2.17M | Buy |
452,777
+119,130
| +36% | +$729K | ﹤0.01% | 1825 |
|
|
2023
Q3 | $2.42M | Sell |
333,647
-103,639
| -24% | -$828K | ﹤0.01% | 1706 |
|
|
2023
Q2 | $3.25M | Buy |
437,286
+151,828
| +53% | +$1.19M | ﹤0.01% | 1615 |
|
|
2023
Q1 | $1.98M | Sell |
285,458
-395,467
| -58% | -$3.64M | ﹤0.01% | 1879 |
|
|
2022
Q4 | $7M | Sell |
680,925
-257,378
| -27% | -$4.54M | 0.01% | 1099 |
|
|
2022
Q3 | $17.1M | Buy |
938,303
+606,480
| +183% | +$26.3M | 0.02% | 713 |
|
|
2022
Q2 | $17.1M | Buy |
331,823
+186,228
| +128% | +$9.65M | 0.02% | 743 |
|
|
2022
Q1 | $10.7M | Sell |
145,595
-22,875
| -14% | -$2.04M | 0.01% | 1015 |
|
|
2021
Q4 | $24.1M | Sell |
168,470
-113,525
| -40% | -$19.5M | 0.01% | 998 |
|
|
2021
Q3 | $58.5M | Buy |
281,995
+91,309
| +48% | +$20.1M | 0.03% | 583 |
|
|
2021
Q2 | $40.5M | Buy |
190,686
+99,822
| +110% | +$18.3M | 0.02% | 790 |
|
|
2021
Q1 | $16.5M | Sell |
90,864
-152,112
| -63% | -$30.3M | 0.01% | 1273 |
|
|
2020
Q4 | $27.1M | Buy |
242,976
+168,329
| +226% | +$17.9M | 0.01% | 1004 |
|
|
2020
Q3 | $8.09M | Sell |
74,647
-18,787
| -20% | -$2.29M | ﹤0.01% | 1494 |
|
|
2020
Q2 | $7.79M | Buy |
+93,434
| New | +$3.57M | 0.01% | 1431 |
|
|
2019
Q4 | – | Sell |
-58,655
| Closed | -$294K | – | 4279 |
|
|
2019
Q3 | $294K | Buy |
58,655
+17,095
| +41% | +$93.6K | ﹤0.01% | 3707 |
|
|
2019
Q2 | $244K | Buy |
41,560
+6,285
| +18% | +$49.5K | ﹤0.01% | 3774 |
|
|
2019
Q1 | $388K | Buy |
35,275
+3,706
| +12% | +$117K | ﹤0.01% | 3473 |
|
|
2018
Q4 | $1.16M | Sell |
31,569
-4,136
| -12% | -$160K | ﹤0.01% | 2670 |
|
|
2018
Q3 | $1.34M | Sell |
35,705
-7,412
| -17% | -$209K | ﹤0.01% | 2649 |
|
|
2018
Q2 | $1.16M | Sell |
43,117
-24,107
| -36% | -$815K | ﹤0.01% | 2905 |
|
|
2018
Q1 | $2.82M | Buy |
67,224
+2,174
| +3% | +$87.3K | ﹤0.01% | 2144 |
|
|
2017
Q4 | $1.61M | Buy |
65,050
+2,792
| +4% | +$68.1K | ﹤0.01% | 2618 |
|
|
2017
Q3 | $1.42M | Buy |
62,258
+10,740
| +21% | +$240K | ﹤0.01% | 2841 |
|
|
2017
Q2 | $1.19M | Sell |
51,518
-24,457
| -32% | -$480K | ﹤0.01% | 2592 |
|
|
2017
Q1 | $1.95M | Buy |
75,975
+26,379
| +53% | +$725K | ﹤0.01% | 2373 |
|
|
2016
Q4 | $1.25M | Sell |
49,596
-8,548
| -15% | -$249K | ﹤0.01% | 2842 |
|
|
2016
Q3 | $2.42M | Buy |
58,144
+10,013
| +21% | +$1.29M | ﹤0.01% | 2240 |
|
|
2016
Q2 | $7M | Sell |
48,131
-10,947
| -19% | -$1.25M | 0.01% | 1402 |
|
|
2016
Q1 | $6.1M | Buy |
59,078
+11,817
| +25% | +$1.27M | 0.01% | 1399 |
|
|
2015
Q4 | $7.93M | Sell |
47,261
-2,153
| -4% | -$331K | 0.01% | 1294 |
|
|
2015
Q3 | $6.99M | Sell |
49,414
-5,444
| -10% | -$1.22M | 0.01% | 1338 |
|
|
2015
Q2 | $12.2M | Buy |
54,858
+37,535
| +217% | +$6.6M | 0.01% | 1116 |
|
|
2015
Q1 | $2.87M | Sell |
17,323
-57,094
| -77% | -$9.27M | ﹤0.01% | 2092 |
|
|
2014
Q4 | $8.82M | Sell |
74,417
-796
| -1% | -$83.2K | 0.01% | 1364 |
|
|
2014
Q3 | $6.27M | Buy |
75,213
+12,159
| +19% | +$1.1M | 0.01% | 1586 |
|
|
2014
Q2 | $5.83M | Buy |
63,054
+37,656
| +148% | +$3.31M | ﹤0.01% | 1822 |
|
|
2014
Q1 | $2.3M | Buy |
25,398
+14,671
| +137% | +$1.64M | ﹤0.01% | 2404 |
|
|
2013
Q4 | $1.1M | Buy |
10,727
+2,100
| +24% | +$148K | ﹤0.01% | 3189 |
|
|
2013
Q3 | $544K | Buy |
8,627
+2,527
| +41% | +$142K | ﹤0.01% | 3450 |
|
|
2013
Q2 | $250K | Buy |
+6,100
| New | +$264K | ﹤0.01% | 3738 |
|
Other funds holding NVAX
SCM
Credit Suisse's NVAX Position: Q1 2024 in Review
Credit Suisse reduced its Novavax (NVAX) stake by 10% in Q1 2024, selling an estimated $218K and leaving 405,846 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.
Credit Suisse first reported a position in NVAX in Q2 2013 and has held it in 42 quarters since. The position peaked at $58.5M in Q3 2021. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.
- Credit Suisse held 405,846 shares of Novavax worth $1.94M as of Q1 2024.
- Credit Suisse sold 46,931 Novavax shares in Q1 2024, an estimated $218K.
- Novavax made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1871 holding.
- Credit Suisse first reported a position in Novavax in Q2 2013 and has held it in 42 quarters since.
- Credit Suisse's Novavax position peaked at $58.5M in Q3 2021.
- 201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.